benaGene Founder Alan Cash
In 2005 following a life-threatening disease, physicist entrepreneur Alan Cash sold his INC 500 company and decided to devote his life and personal funds to researching aging and wellness.
Scouring the scientific journals Cash uncovered research in the Krebs cycle that suggested a ketone, “oxaloacetate”, could dramatically impact cellular energy production and increase the NAD+ / NADH ratio to favorably modify metabolism.
With significant implications for human health, Cash and his team clamored to research oxaloacetate supplementation further but hit a roadblock. Oxaloacetate quickly degraded if not stored in extremely low temperatures, making it too unreliable for study.
Cash established Terra Biological LLC and he engineered and patented a method to thermally stabilize oxaloacetate by creating Anhydrous Enol-Oxaloacetate (AEO). Currently, Terra Biological and Cash hold over 30 patents in oxaloacetate use, including a composition of matter patent.
The discovery allowed the creation of benaGene, the world’s first Oxaloacetate metabolite available in a shelf-stable, bioavailable supplement. Since its creation, Cash and Terra Biological, LLC. has made possible dozens of human and animal studies and Clinical Trials investigating the potential of oxaloacetate.
As more research is published each year, more doctors recommend benaGene to their patients to optimize health on a cellular level. Available over the counter, more than 5,000 doctors and health professionals recommend benaGene and more than 5 million doses have been used worldwide.